SCHEMBL8287296

SCHEMBL8287296

C=C1c2ccccc2C(=O)c2c(NC(C)=O)ccc(NN)c21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.58
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
MMP14 P50281 1/20 0.46
TERT O14746 5/20 0.45
CASP3 P42574 1/20 0.45
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
PHLPP2 Q6ZVD8 1/20 0.43
HSP90AA1 P07900 2/20 0.42
HSP90AB1 P08238 2/20 0.42
NPC1 O15118 1/20 0.42
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
P2RY2 P41231 2/20 0.42
NSD2 O96028 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6370986 0.85 MAOA (0.77) MAOAMEN1KMT2AMMP14TERT
SCHEMBL13564105 0.81 MAOA (0.71) MAOAMEN1KMT2AMMP14TERT
SCHEMBL20978637 0.80 MAOA (0.79) MAOAMEN1KMT2ATERTCASP3
SCHEMBL8777722 0.80 MEN1 (0.69) MAOAMEN1KMT2AMMP14TERT
SCHEMBL11880339 0.78 MAOA (0.67) MAOAMEN1KMT2AMMP14TERT
SCHEMBL5100271 0.77 MAOA (0.65) MAOAMEN1KMT2AMMP14TERT
SCHEMBL8604260 0.77 MAOA (0.65) MAOAMEN1KMT2AMMP14TERT
SCHEMBL8265833 0.76 ALDH1A1 (0.50) MAOAMEN1KMT2AMMP14TERT
SCHEMBL12118723 0.75 MAOA (0.63) MAOAMEN1KMT2AMMP14TERT
SCHEMBL11568163 0.75 MAOA (0.63) MAOAMEN1KMT2AMMP14TERT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007079185-A2 IMPROVED COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION ANTHROGENESIS CORPORATION (US) 2007-07-12 WO disclosed
WO-2005046594-A2 METHODS OF USING AND COMPOSITIONS COMPRISING A JNK INHIBITOR FOR THE TREATMENT AND MANAGEMENT OF ASBESTOS-RELATED DISEASES AND DISORDERS CELGENE CORPORATION (US) 2005-05-26 WO disclosed
WO-2004041191-A2 METHODS FOR THE TREATMENT, PREVENTION AND MANAGEMENT OF MACULAR DEGENERATION CELGENE CORPORATION (US) 2004-05-21 WO disclosed
WO-2003102151-A2 MODULATING CELL DIFFERENTIATION AND TREATING MYELOPROLIFERTIVE DISORDERS WITH JNK/MKK INHIBITORS CELGENE CORPORATION (US) 2003-12-11 WO disclosed
WO-2003099221-A2 METHODS FOR USING JNK INHIBITORS FOR TREATING OR PREVENTING DISEASE-RELATED WASTING SIGNAL PHARMACEUTICALS, INC. (US) 2003-12-04 WO disclosed